title: [FUNCTIONAL ACTIVITY OF EHRLICH CARCINOMA CELLS AFTER TREATMENT WITH HYBRID NANOCOMPLEXES CONTAINING ORTHOVANADATES OF RARE-EARTH ELEMENTS, CHOLESTEROL AND LUMINESCENT DYE].
abstract: Tumor development is the consequence of expanding the population of low differentiated cells with unlimited self-maintenance potential, i.e. cancer stem cells (CSCs). Application of new forms of nanocomposites capable of binding to CSCs and inducing the tumor destruction is perspective direction for treating this pathology. There have been developed the methods of obtaining hybrid nanocomplexes containing rare-earth orthovanadates GdYVO4:Eu³⁺, cholesterol and luminescent dye Dil. By immune fluorescence method using monoclonal antibodies to CD44, CD24, CD117 and Sca-1 markers there has been established the change in the ratio of tumor progenitors of various differentiation levels in a general pool of Ehrlich carcinoma (EC) after treatment with hybrid nanocomplexes. Essential reduction in the concentration of the most tumorogenic CD44high cells with simultaneous rise in the number of CD117⁺-cells resulted in an increased index of CD44high/CD117⁺ ratio. It has been demonstrated that application of hybrid nanocomplexes suppressed the tumor growth almost by 80%. The value of cooperative interactions of the cells with different phenotype signs in tumor sites has been proved. The index of CD44high/CD117⁺ ratio can be used as one of diagnostic and prognostic parameters of development and inactivation rate of tumor process when using different types of anti-tumor therapy.
authors.forename: A N
authors.initials: AN
authors.lastname: Goltsev
authors.forename: N N
authors.initials: NN
authors.lastname: Babenko
authors.forename: A
authors.initials: A
authors.lastname: Gaevskaya
authors.forename: O V
authors.initials: OV
authors.lastname: Chelombitko
authors.forename: N A
authors.initials: NA
authors.lastname: Bondarovich
authors.forename: T G
authors.initials: TG
authors.lastname: Dubrava
authors.forename: M V
authors.initials: MV
authors.lastname: Ostankov
authors.forename: V K
authors.initials: VK
authors.lastname: Klochkov
authors.forename: N S
authors.initials: NS
authors.lastname: Kavok
authors.forename: Yu V
authors.initials: YV
authors.lastname: Malyukin
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000737:chemistry; D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor / Q000235:genetics* / Q000378:metabolism; D002232:Carbocyanines / Q000737:chemistry; D002286:Carcinoma, Ehrlich Tumor / Q000188:drug therapy* / Q000235:genetics / Q000401:mortality / Q000473:pathology; D002784:Cholesterol / Q000737:chemistry; D005063:Europium / Q000737:chemistry; D005260:Female; D005682:Gadolinium / Q000737:chemistry; D015870:Gene Expression; D018960:Hyaluronan Receptors / Q000235:genetics* / Q000378:metabolism; D049449:Luminescence; D051379:Mice; D008807:Mice, Inbred BALB C; D053769:Nanocapsules / Q000737:chemistry / Q000627:therapeutic use*; D009368:Neoplasm Transplantation; D014411:Neoplastic Stem Cells / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology; D019009:Proto-Oncogene Proteins c-kit / Q000235:genetics* / Q000378:metabolism; D016019:Survival Analysis; D014638:Vanadates / Q000737:chemistry
chemical_list: C582073:1,1'-dioleyl-3,3,3',3'-tetramethylindocarbocyanine; D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D002232:Carbocyanines; C476399:Cd44 protein, mouse; D018960:Hyaluronan Receptors; D053769:Nanocapsules; D014638:Vanadates; D005063:Europium; D002784:Cholesterol; D005682:Gadolinium; D019009:Proto-Oncogene Proteins c-kit